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ECONOMIC AND OUTCOMES ISSUES
ON DIABETES
PDD1
DISEASE MANAGEMENT PATTERNS OF TYPE 2 
DIABETIC PATIENTS IN AN ACADEMIC FAMILY 
MEDICINE CENTER
Longe RL1, Taylor AT1, Wagner PJ2, Mongan PF2
1University of Georgia, Athens, GA, USA; 2Medical College of 
Georgia, Augusta, GA, USA
OBJECTIVE: Analyze diabetic management patterns in
an academic family medicine center (FMC). 
METHOD: Type 2 diabetics (N  116) visiting FMC
during January 1997 were included. Medical records
from January–December 1997 were reviewed retrospec-
tively. Data included self-monitoring blood glucose
(SMBG), diet, exercise, and drug usage patterns.
RESULTS: The sample had a mean age of 61 years with
15% 45 years, 44% between 45–65 years, and 41%
65, with 53% African American, 45% white, and 69%
female. Physicians reported SMBG in 76% of the patients
at least once yearly with 28 patients not reporting. Dietary
management was documented in 65% of the patients and
exercise planning in 35%. Younger patients were more
likely to receive diet recommendations (89% age 45,
65% age 45–64, 55% age 65), and exercise recommen-
dations (55% age 45, 27% age 45–64, 23% age 65).
Physicians prescribed 108 patients an antidiabetic drug
with 8 patients on diet-exercise alone. Seventy-two percent
were prescribed an oral hypoglycemic drug and 29% with
insulin. Physicians treated 92 patients with a single drug,
23 patients used two drugs, and 1 patient received three
drugs. Glyburide (23%), glipizide (36%), and NPH (19%)
were the most frequent single agents prescribed; NPH with
regular insulin was the most frequent combination. Sixty
percent of patients were prescribed an angiotensin convert-
ing enzyme inhibitor (ACE-I). Fifty-six of 91 hypertensive
patients were treated with an ACE-I. Eleven patients were
prescribed a beta blocker (BB) drug. Of the four patients
with history of MI, two were using a BB. 
CONCLUSION: Disease management patterns varied. Fu-
ture management strategies should address SMBG, diet,
exercise, and potentially beneficial drug therapy, unless
contraindicated.
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PSYCHOMETRIC PROPERTIES OF THE PATIENT 
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OF DIABETIC PERIPHERAL NEUROPATHY (DPN) 
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OBJECTIVE: Assess the psychometric properties of a
newly developed questionnaire (the PBQ) in a group of
patients diagnosed with DPN. 
METHODS: An instrument was developed to assess the
effect of DPN on the patient’s perception of symptoms,
activities of daily living (ADL), and health related quality
of life (QOL). Expert panel review and nine patient focus
groups indicated that the instrument had face/content va-
lidity. In this study 222 patients being screened for inclu-
sion into a clinical trial completed the instrument. 
RESULTS: The rate of missing values was 3% to 5%,
with Pain Severity Scale for Hands and Arms having the
highest rate. Item-discriminant validity tests indicated that
98% of the items were scaling successes. The possible scal-
ing failures are associated with two scales (Numbness and
Tingling for feet and legs, and Numbness/Tingling for
hands and arms). Cronbach’s alpha ranged from 0.67 to
0.94. Scale correlations and Cronbach’s alpha in parenthe-
ses for the partial symptom section are provided below.
Interscale correlations followed a priori patterns. Psycho-
metric characteristics of the ADL and QOL sections were
as predicted.
CONCLUSIONS: The newly developed PBQ in this co-
hort of DPN patients exhibits the psychometric proper-
ties of reliability, validity, and responsiveness.
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A COST-OF-TREATMENT MODEL FOR 
TYPE 2 DIABETES
Stephens JM1, Botteman MF1, Ramsdell JW2, Grossman JA3, 
Arocho R4
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Cost-effective management of diabetes is extremely impor-
tant for MCOs; however, little is known regarding the
short-term economic impact of oral antidiabetic agents. 
OBJECTIVE: The purpose of the study was to compare,
from an MCO perspective, the 3-year costs of three first-
line monotherapy strategies in newly diagnosed type 2 di-
abetes patients: glipizide GITS, metformin, or acarbose. 
METHODS: A literature-based Markov model using
10,000 Monte Carlo simulations (assuming triangular
distributions for the variables) was developed to compare
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Sen F/L (0.85)
Sen H/A 0.69 (0.88)
N/T F&L 0.43 0.29 (0.67)
N/T H&A 0.27 0.49 0.48 (0.74)
Fq pain F/L 0.35 0.27 0.63 0.26 (0.74)
Fq pain H/A 0.33 0.46 0.45 0.70 0.49 (0.84)
Sev pain F/L 0.56 0.45 0.53 0.38 0.54 0.443 (0.84)
Sev pain H/A 0.47 0.62 0.23 0.53 0.20 0.53 0.64 (0.87)
6-mo Sx F/L 0.76 0.62 0.57 0.38 0.46 0.42 0.73 0.53 (0.93)
